Literature DB >> 2566048

Double-masked trial of cyclosporin versus colchicine and long-term open study of cyclosporin in Behçet's disease.

K Masuda1, A Nakajima, A Urayama, K Nakae, M Kogure, G Inaba.   

Abstract

The efficacy and safety of oral cyclosporin 10 mg/kg per day in Behçet's disease were compared in a randomised double-masked study with those of colchicine, 1 mg orally per day, and were also investigated in a long-term open study. The double-masked study showed that cyclosporin was effective in treating not only the ocular manifestations of Behçet's disease but also oral aphthous ulcer, dermal lesions, and genital ulceration. Efficacy did not weaken during long-term treatment.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2566048     DOI: 10.1016/s0140-6736(89)92381-7

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  95 in total

Review 1.  Behçet's disease: immunopathologic and therapeutic aspects.

Authors:  Robert Meador; George Ehrlich; Joan M Von Feldt
Journal:  Curr Rheumatol Rep       Date:  2002-02       Impact factor: 4.592

Review 2.  Behçet's disease.

Authors:  V Kontogiannis; R J Powell
Journal:  Postgrad Med J       Date:  2000-10       Impact factor: 2.401

Review 3.  The use of immunosuppressive and cytotoxic drugs in non-malignant disease.

Authors:  P A Brogan; M J Dillon
Journal:  Arch Dis Child       Date:  2000-09       Impact factor: 3.791

4.  Behçet's Disease.

Authors: 
Journal:  Curr Treat Options Neurol       Date:  2000-09       Impact factor: 3.598

5.  Low dose cyclosporin A versus pulsed cyclophosphamide in Behçet's syndrome: a single masked trial.

Authors:  Y Ozyazgan; S Yurdakul; H Yazici; B Tüzün; A Işçimen; Y Tüzün; T Aktunç; H Pazarli; V Hamuryudan; A Müftüoğlu
Journal:  Br J Ophthalmol       Date:  1992-04       Impact factor: 4.638

6.  Behçet's disease.

Authors:  B Wechsler; J C Piette
Journal:  BMJ       Date:  1992-05-09

Review 7.  Colchicine--expanding horizons.

Authors:  A Schattner
Journal:  Postgrad Med J       Date:  1991-03       Impact factor: 2.401

Review 8.  Behçet's syndrome.

Authors:  Yusuf Yazici; Sebahattin Yurdakul; Hasan Yazici
Journal:  Curr Rheumatol Rep       Date:  2010-12       Impact factor: 4.592

9.  Human recombinant interferon alfa-2a for the treatment of Behçet's disease with sight threatening posterior or panuveitis.

Authors:  I Kötter; M Zierhut; A K Eckstein; R Vonthein; T Ness; I Günaydin; B Grimbacher; S Blaschke; W Meyer-Riemann; H H Peter; N Stübiger
Journal:  Br J Ophthalmol       Date:  2003-04       Impact factor: 4.638

10.  Treatment of ocular symptoms of Behçet's disease with interferon alpha 2a: a pilot study.

Authors:  I Kötter; A K Eckstein; N Stübiger; M Zierhut
Journal:  Br J Ophthalmol       Date:  1998-05       Impact factor: 4.638

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.